<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Enliven Therapeutics Inc. — News on 6ix</title>
    <link>https://6ix.com/company/enliven-therapeutics-inc</link>
    <description>Latest news and press releases for Enliven Therapeutics Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 03 Mar 2026 21:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/enliven-therapeutics-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683562dd78dffbe2df0ef033.webp</url>
      <title>Enliven Therapeutics Inc.</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc</link>
    </image>
    <item>
      <title>Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-business-update</guid>
      <pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
      <description>Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update, including highlights of positive initial data from the ongoing Phase 1b ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that is relapsed, refractor</description>
    </item>
    <item>
      <title>Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
      <pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
      <description>Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 10:30 a.m. ET.</description>
    </item>
    <item>
      <title>Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-reports-positive-initial-phase-1b-data-elvn-001-cml-and-outlines-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-reports-positive-initial-phase-1b-data-elvn-001-cml-and-outlines-2026</guid>
      <pubDate>Thu, 08 Jan 2026 05:00:00 GMT</pubDate>
      <description>Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b</description>
    </item>
    <item>
      <title>Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-bolsters-board-prepare-next-phase-development-2026-01-07</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-bolsters-board-prepare-next-phase-development-2026-01-07</guid>
      <pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
      <description>Scott Garland, a seasoned biopharma executive with a strong track record of leading successful companies and drug launches, joins Enliven&apos;s Board of</description>
    </item>
    <item>
      <title>Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-2025-12</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-inducement-grants-permitted-nasdaq-listing-rules-2025-12</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (&quot;Enliven&quot;), (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces New CEO to Drive Next Phase of Development</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-new-ceo-drive-next-phase-development-2025-12-11</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-new-ceo-drive-next-phase-development-2025-12-11</guid>
      <pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
      <description>Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive Officer Co-Founder</description>
    </item>
    <item>
      <title>/C O R R E C T I O N -- Enliven Therapeutics, Inc./</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-enliven-therapeutics-inc-2025-11-12</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/c-o-r-r-e-c-t-i-o-n-enliven-therapeutics-inc-2025-11-12</guid>
      <pubDate>Wed, 12 Nov 2025 05:00:00 GMT</pubDate>
      <description>In the news release, Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update, issued 12-Nov-2025 by Enliven Therapeutics,</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Clinical Data in CML Patients with Atypical Fusion Transcripts at ASH 2025 Annual Meeting</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-clinical-data-cml-patients-atypical-fusion-transcripts</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-clinical-data-cml-patients-atypical-fusion-transcripts</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcripts Growing unmet need for patients with</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2025 Annual Meeting</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-oral-and-poster-presentations-society-hematologic</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-oral-and-poster-presentations-society-hematologic</guid>
      <pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., Aug. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-second-quarter-financial-results-and-provides-business</guid>
      <pubDate>Wed, 13 Aug 2025 04:00:00 GMT</pubDate>
      <description>Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters&apos; Option to Purchase Additional Shares</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-closing-public-offering-common-stock-and-pre-funded</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-closing-public-offering-common-stock-and-pre-funded</guid>
      <pubDate>Mon, 16 Jun 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., June 16, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-pricing-public-offering-common-stock-and-pre-funded</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-pricing-public-offering-common-stock-and-pre-funded</guid>
      <pubDate>Fri, 13 Jun 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-proposed-public-offering-common-stock-and-pre-funded</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-proposed-public-offering-common-stock-and-pre-funded</guid>
      <pubDate>Fri, 13 Jun 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., June 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML at EHA 2025 Congress</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-updated-positive-data-phase-1-clinical-trial-elvn-0</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-updated-positive-data-phase-1-clinical-trial-elvn-0</guid>
      <pubDate>Fri, 13 Jun 2025 04:00:00 GMT</pubDate>
      <description>Reported cumulative MMR rate of 47% (25 of 53) by 24 weeks with 32% (13 of 41) of patients achieving MMR by 24 weeks, which continues to compare favorably to</description>
    </item>
    <item>
      <title>Enliven Therapeutics to Present at Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-present-upcoming-investor-conferences-2025-05-22</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-present-upcoming-investor-conferences-2025-05-22</guid>
      <pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., May 22, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-business</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-first-quarter-financial-results-and-provides-business</guid>
      <pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
      <description>Updated data from the Phase 1 ENABLE clinical trial of ELVN-001 in CML to be presented at the EHA 2025 Congress in June EHA abstract reported cumulative MMR</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Updated Positive Data from Phase 1 Clinical Trial of ELVN-001 in CML and Oral Presentation at the EHA 2025 Congress</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-updated-positive-data-phase-1-clinical-trial-elvn-001</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-updated-positive-data-phase-1-clinical-trial-elvn-001</guid>
      <pubDate>Wed, 14 May 2025 04:00:00 GMT</pubDate>
      <description>Reported cumulative MMR rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving MMR by 24 weeks, which continues to compare favorably to</description>
    </item>
    <item>
      <title>Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-poster-presentations-2025-aacr-annual-meeting-2025-04</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-announces-poster-presentations-2025-aacr-annual-meeting-2025-04</guid>
      <pubDate>Wed, 02 Apr 2025 04:00:00 GMT</pubDate>
      <description>BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
    <item>
      <title>Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and</guid>
      <pubDate>Thu, 13 Mar 2025 04:00:00 GMT</pubDate>
      <description>Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002</description>
    </item>
    <item>
      <title>Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference</title>
      <link>https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-present-td-cowen-45th-annual-health-care-conference-2025-02-25</link>
      <guid isPermaLink="true">https://6ix.com/company/enliven-therapeutics-inc/news/enliven-therapeutics-present-td-cowen-45th-annual-health-care-conference-2025-02-25</guid>
      <pubDate>Tue, 25 Feb 2025 05:00:00 GMT</pubDate>
      <description>BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company</description>
    </item>
  </channel>
</rss>